Inclusion Criteria:

• Ovarian patients:

  • Patients with epithelial ovarian, primary peritoneal, fallopian tube or mixed mullerian cancer of ovarian origin in need of relapse treatment

• Bladder patients:

  • Patients with urothelial (transitional cell) cancer of the bladder

• All Patients:

  • At least one measurable uni-dimensional lesion
  • ECOG status ≤ 2
  • Life expectancy ≥ 3 months
  • Age ≥ 18 years

  • Acceptable liver, renal and bone marrow function:

    • Bilirubin ≤ 1.5 x ULN
    • AST (SGOT), ALT (SGPT) and Alkaline Phosphatase ≤ 3 x ULN. If liver metastases are present then ≤ 5 x ULN is allowed.
    • Measured EDTA renal clearance ≥ 45 mL/min (within EU).
    • Creatinine clearance ≥ 45 mL/min (within USA)
  • Leucocytes > 2.5 x 109/ L
  • Neutrophils > 1.0 x 109/L
  • Platelets > 100 x 109/L
  • Hemoglobin > 9.0 g/dL or > 5.6 mmol/l
  • Acceptable coagulation status
  • Negative pregnancy test/use of effective contraceptive methods for women of childbearing potential.
  • Serum potassium within normal range

Exclusion Criteria:

• More than three prior lines of chemotherapy given for metastatic disease
• History of a concurrent second malignancy
• History of hypersensitivity to either platinum or paclitaxel that cannot be desensitized

• Co-existing active infection or any co-existing medical condition likely to interfere with trial procedures, including:

  • significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease)
  • myocardial infarction within the past 6 months
  • unstable angina
  • congestive heart failure requiring therapy
  • unstable arrhythmia or a need for anti-arrhythmic therapy
  • evidence of ischemia on ECG
  • marked baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc interval > 500 msec;
  • long QT Syndrome
  • required use of concomitant medication on PXD101 infusion days that may cause Torsade de Pointes.
• Bowel obstruction or impending bowel obstruction
• Known HIV positivity
• Mixed mullerian cancer of intra-uterine origin
• Any existing grade 2 or above drug-related neurotoxicity due to prior treatment with agents causing neurotoxicity
• Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
• Treatment with investigational agents within the last 4 weeks
• Prior anticancer therapy within the last 3 weeks of trial dosing including chemotherapy, radiotherapy, endocrine therapy or immunotherapy